Home > Healthcare & Medical Devices > Automated Cell Counter Market
Automated Cell Counter Market size exceeded USD 6 billion in 2021 and is anticipated to expand at over 4.5% CAGR from 2022 to 2030. The growing prevalence of infectious and chronic diseases is seen as a pivotal factor boosting market expansion.
To get more details on this report: Request Free Sample PDF
The increased adoption of sedentary lifestyle, changing dietary preferences, and rising tobacco and alcohol consumption have resulted in surging incidences of chronic health conditions. The growing implications on healthcare resources as a result of the increasing disease burden have propelled the demand for advanced diagnostic tools.
Report Coverage | Details |
---|---|
Base Year: | 2021 |
Market Size in 2021: | USD 6 Billion |
Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 4.5% |
2030 Value Projection: | USD 9 Billion |
Historical Data for: | 2017 to 2021 |
No. of Pages: | 165 |
Tables, Charts & Figures: | 198 |
Segments covered: | Product Type, Application, End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
To get more details on this report: Request Free Sample PDF
With constant technological innovations in order to reduce errors and improve efficiency, the cost of automated cell counter devices is going up. For instance, a flow cytometer device is available at an average price of USD 75,000 to USD 90,000. Such a surge in device cost as well as rise in price of accessories are decelerating the adoption rate of automated cell counters, which is a major challenge that may restrain the industry revenue.
To get more details on this report: Request Free Sample PDF
Based on products, the automated cell counter market is fragmented into fluorescence image-based cell counters, flow cytometers, and coulter counters. The fluorescence image-based cell counter segment is anticipated to register 4% CAGR during the projection period. For general-purpose cell counting applications, image-based cell counters are far more capable than their flow-based counterparts. Besides, they require no maintenance, provide ease of use, and are relatively more cost-effective. These remarkable product attributes, coupled with the increasing incidences of UTIs (Urinary Tract Infections), diabetes, kidney diseases, and other chronic conditions, may drive lucrative gains to the industry.
To get more details on this report: Request Free Sample PDF
In terms of applications, the automated cell counter market is classified into blood cells, cell lines, microbial cells, and others. The blood cell segment held over 45% of the revenue share in 2021 and is projected to record a lucrative CAGR in the coming years. Blood cell counting has emerged as a dependable and effective technique across the healthcare environment due to its extensive utilization in evaluating a person's overall health. Alongside a broad range of applications in clinical and research practice, the technique has proved beneficial in detecting several health disorders, such as infection, anemia, and leukemia, which is pushing the demand for automated cell counters for blood cells.
With regards to the end-user, automated cell counters are widely used across hospitals, diagnostic laboratories, research institutes, pharmaceuticals & biotechnology companies, and others. The diagnostic laboratories segment is poised to account for over 17% business share by 2030. Diagnostic centers are equipped with skilled staff, trained medical professionals, and advanced laboratory equipment, helping patients with particular signs or symptoms to identify diseases. The increasing number of people of all age groups and genders undergoing disease diagnosis across these settings will help the segment growth gain significant impetus.
Europe automated cell counter market is projected to exceed USD 2.4 billion by 2030. This is attributed to the expanding geriatric populace and their greater susceptibility to several chronic health conditions. In addition, the rising health concerns, increasing medical expenditure, and the ongoing improvement in the existing healthcare infrastructure may push the adoption of automated cell counters across Europe.
Prominent players operating in the automated cell counter market include Abbott Laboratories, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc, Danaher (Beckman Coulter Inc. and Radiometer), Sysmex Corporation, NanoEnTek, F. Hoffmann-La Roche Ltd, Olympus Corporation, Agilent Technologies, Inc., PerkinElmer, Inc.
As a part of their primary growth strategy, these companies are leveraging advanced technologies to introduce cutting-edge products with enhanced precision and accuracy into the market. This will help strengthen their global presence and safeguard their position in the market. For instance, in May 2021, Bio-Rad Laboratories, Inc. launched FCS Express flow cytometry analysis software for the ZE5 cell analyzer. The software helped researchers analyze output publication-quality graphics and high parameter data sets while assisting a quick conversion from raw results to publication.
The onset of the COVID-19 pandemic had a favorable impact on the automated cell counter industry. The unpredictable clinical course of the coronaviral infection and the absence of any preventive therapy and treatment resulted in the increasing number of research & development projects across the biomedical and life science sector, fostering the demand for automated cell counters. Analysis of several hematological parameters, including platelets, lymphocytes, white blood cell count, neutrophils, and hemoglobin, emerged as an effective clinical practice to determine disease severity.
The automated cell counter market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2030, for the following segments: Click here to Buy Section of this Report
By Product Type
By Application
By End-use
The above information is provided for the following regions and countries: